MA53381A - Association d'inhibiteurs de la voie lilrb1/2 et d'inhibiteurs de la voie pd-1 - Google Patents

Association d'inhibiteurs de la voie lilrb1/2 et d'inhibiteurs de la voie pd-1

Info

Publication number
MA53381A
MA53381A MA053381A MA53381A MA53381A MA 53381 A MA53381 A MA 53381A MA 053381 A MA053381 A MA 053381A MA 53381 A MA53381 A MA 53381A MA 53381 A MA53381 A MA 53381A
Authority
MA
Morocco
Prior art keywords
inhibitors
path
path inhibitors
lilrb1
association
Prior art date
Application number
MA053381A
Other languages
English (en)
Inventor
Ian Halsey Driver
Jackson Graeme Egen
Chi-Ming Kevin Li
Wenjun Ouyang
Shunsuke Takenaka
Christy Ann Thomson
Hongyu Wang
Oh Kyu Yoon
Xin Yu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA53381A publication Critical patent/MA53381A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA053381A 2018-07-24 2019-07-17 Association d'inhibiteurs de la voie lilrb1/2 et d'inhibiteurs de la voie pd-1 MA53381A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862702493P 2018-07-24 2018-07-24
US201962872431P 2019-07-10 2019-07-10

Publications (1)

Publication Number Publication Date
MA53381A true MA53381A (fr) 2021-06-02

Family

ID=67551695

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053381A MA53381A (fr) 2018-07-24 2019-07-17 Association d'inhibiteurs de la voie lilrb1/2 et d'inhibiteurs de la voie pd-1

Country Status (4)

Country Link
US (1) US20210301020A1 (fr)
EP (1) EP3827020A1 (fr)
MA (1) MA53381A (fr)
WO (1) WO2020023268A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018127919A1 (fr) 2017-01-05 2018-07-12 Kahr Medical Ltd. Protéine de fusion sirp1 alpha-41bbl et leurs procédés d'utilisation
WO2018127916A1 (fr) 2017-01-05 2018-07-12 Kahr Medical Ltd. Protéine de fusion pd1-cd70 et ses procédés d'utilisation
LT3565579T (lt) 2017-01-05 2023-09-11 Kahr Medical Ltd. Pd1-41bbl sulietas baltymas ir jo panaudojimo būdai
AU2019302454A1 (en) 2018-07-09 2021-02-25 Bristol-Myers Squibb Company Antibodies binding to ILT4
CA3104780A1 (fr) 2018-07-11 2020-01-16 Kahr Medical Ltd. Proteine de fusion du variant de sirpalpha-4-1bbl et procedes d'utilisation associes
US12286466B2 (en) 2018-07-11 2025-04-29 Kahr Medical Ltd. PD1-4-1BBL variant fusion protein and methods of use thereof
US20220025056A1 (en) * 2018-12-26 2022-01-27 Innate Pharma Leucocyte immunoglobulin-like receptor neutralizing antibodies
PH12022550333A1 (en) 2019-08-12 2023-06-14 Biond Biologics Ltd Antibodies against ilt2 and use thereof
MY209480A (en) 2020-05-01 2025-07-11 Ngm Biopharmaceuticals Inc Ilt-binding agents and methods of use thereof
BR112023002301A2 (pt) 2020-08-12 2023-10-03 Biond Biologics Ltd Anticorpos contra ilt2 e uso dos mesmos
KR20240006541A (ko) * 2021-04-09 2024-01-15 셀덱스 쎄라퓨틱스, 인크. Ilt4에 대한 항체, 이중특이적 항-ilt4/pd-l1 항체 및 이의 용도
WO2023077521A1 (fr) * 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Constructions bispécifiques anti-ilt4 et anti-pd-1
EP4486383A2 (fr) * 2022-03-04 2025-01-08 D2M Biotherapeutics Limited Anticorps anti-lilrb1/2 et leurs utilisations
WO2023170434A1 (fr) 2022-03-11 2023-09-14 Macomics Limited Compositions et procédés pour moduler l'activité des macrophages
CN121532420A (zh) * 2023-04-13 2026-02-13 昂科里斯庞斯公司 Lilrb2/1抗体产品和方法
WO2025113640A1 (fr) * 2023-11-30 2025-06-05 南京维立志博生物科技股份有限公司 Anticorps se liant à lilrb1/2 ou pd1-lilrb1/2 et son utilisation
WO2026003224A2 (fr) 2024-06-26 2026-01-02 Iomx Therapeutics Ag Protéines bispécifiques de liaison à l'antigène (abp) ciblant des molécules de point de contrôle immunitaire et à la fois la sous-famille b1 des récepteurs de type immunoglobuline leucocytaire (lilrb1) et lilrb2; combinaisons et utilisations associées

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666865A (en) 1984-01-13 1987-05-19 Centocor, Inc. Immunoassay for biologically active human interferon-gamma employing unique monoclonal antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
EP1257289A1 (fr) 2000-02-08 2002-11-20 The Penn State Research Foundation Utilisation du recepteur de l'interleukine 13, sous-unite alpha 2, dans l'immunotherapie
KR20120053525A (ko) * 2000-06-16 2012-05-25 캠브리지 안티바디 테크놀로지 리미티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
ES2729974T3 (es) 2003-01-23 2019-11-07 Ono Pharmaceutical Co Anticuerpo específico de PD-1 y CD3 humanas
CN103059138B (zh) 2005-05-09 2015-10-28 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
WO2007005874A2 (fr) 2005-07-01 2007-01-11 Medarex, Inc. Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
EP3222634A1 (fr) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Anticorps dirigés contre le récepteur humain de mort programmée pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
BRPI0917891A2 (pt) 2008-08-25 2015-11-24 Amplimmune Inc antagonistas de pd-1 e métodos de utilização dos mesmos
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
NZ717213A (en) 2008-12-09 2017-10-27 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
DE102011009470A1 (de) 2011-01-21 2012-08-09 Friedrich-Schiller-Universität Jena Biologisch wirksame Nukleotid-Moleküle zur gezielten Abtötung von Zellen, Verwendung derselben sowie Applikationskit
WO2013019906A1 (fr) 2011-08-01 2013-02-07 Genentech, Inc. Procédés de traitement du cancer à l'aide d'antagonistes se liant à l'axe pd-1 et inhibiteurs de mek
EP2730588A1 (fr) 2012-11-12 2014-05-14 Intelectys Anticorps et fragments de ceux-ci dirigés contre le domaine alpha-3 de protéine HLA-G, procédés et moyens pour leur préparation et leurs utilisations
TW201613635A (en) 2014-02-04 2016-04-16 Pfizer Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
US10316094B2 (en) * 2014-10-24 2019-06-11 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance
AU2016229201B2 (en) * 2015-03-06 2021-01-28 The Board Of Regents Of The University Of Texas System Anti-LILRB antibodies and their use in detecting and treating cancer
WO2016179194A1 (fr) * 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 et son procédé d'utilisation
CN109563169B (zh) 2016-06-03 2022-07-01 英韦克泰斯公司 抗hla-g特异性抗体
TWI796329B (zh) * 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
WO2019140196A1 (fr) * 2018-01-12 2019-07-18 Amgen Inc. Anticorps anti-pd1 et méthodes de traitement
CR20210047A (es) * 2018-07-02 2021-05-21 Amgen Inc Proteína de unión al antígeno anti-steap1

Also Published As

Publication number Publication date
EP3827020A1 (fr) 2021-06-02
US20210301020A1 (en) 2021-09-30
WO2020023268A1 (fr) 2020-01-30

Similar Documents

Publication Publication Date Title
MA53381A (fr) Association d'inhibiteurs de la voie lilrb1/2 et d'inhibiteurs de la voie pd-1
EP3454844A4 (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-1
MA51066A (fr) Inhibiteurs d'intégrine
MA44990A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1
MA55136A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
IL283592A (en) Inhibitors of apol1 and methods of using same
EP3804389A4 (fr) Détermination et publication dynamiques d'amf de secours
EP3870178A4 (fr) Formes cristallines d'inhibiteurs de mnk
EP3756379C0 (fr) Notification spécifique de sftd et d'anr
MA53388A (fr) Inhibiteurs d'inflammasome nlrp3
EP3684361A4 (fr) Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
IL288996A (en) Aminopyrimidine amide autophagy inhibitors and methods of use thereof
EP3962479A4 (fr) Inhibiteurs de kcnt1 et procédés d'utilisation
EP3634430A4 (fr) Agents multibiotiques et procédés d'utilisation de ceux-ci
MA49773A (fr) Combinaisons d'antagonistes de pd-1 et d'agonistes de sting benzo[b
HRP20251592T1 (hr) Inhibitori arginaze i metode njihove primjene
EP3452597A4 (fr) Procédés et compositions d'agents biologiquement actifs
EP3429591A4 (fr) Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
EP3630287A4 (fr) Inhibiteurs de parp radiomarqués et fluorescents pour l'imagerie et la radiothérapie
MA45688A (fr) Compositions et procédés de potentialisation d'agents antimicrobiens
MA51417A (fr) Constructions d'anticorps bispécifiques dirigés contre muc17 et cd3
EP3846808A4 (fr) Inhibiteurs de papd5 et leurs procédés d'utilisation
EP3609864A4 (fr) Inhibiteurs de hdac6 et agents d'imagerie
EP3802489A4 (fr) Inhibiteurs de masp -2 et procédés d'utilisation
EP3765006A4 (fr) Inhibiteurs d'arginase et procédés d'utilisation